Kyverna Therapeutics closed at $5.16 on Nov 4, unchanged, within 0.0% of its 52-week closing low. Volume of 973.3K shares was 1.16× its 20-day average (close to normal).
Split-adjusted performance: -16.2% over one month, -45.5% over six months, -25.0% over one year.
Short interest was 9.5M shares at the Oct 15 settlement (26.6% of float, 10.5 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KYTXKyverna Therapeutics | $5.16 | 0.00% | −45.5% | — | — | — | $319.1M | |
| SCTXScribe Therapeutics | $16.78 | +3.58% | — | — | — | — | $317.7M | Compare |
| XFORX4 Pharmaceuticals | $3.24 | +2.21% | −26.0% | +346.3% | −183.5% | — | $321.2M | Compare |
| AGENAgenus | $6.97 | +4.50% | +79.2% | +34.4% | −1.7% | 3.4 | $314.8M | Compare |
| IPSCCentury Therapeutics | $1.67 | +9.87% | −28.6% | — | — | — | $302.4M | Compare |
| OCGNOcugen | $0.8745 | +17.35% | −39.9% | +8.4% | −1671.8% | — | $296.6M | Compare |
| EIKNEikon Therapeutics | $6.39 | +15.14% | −35.9% | — | — | — | $346.1M | Compare |
| SABSSAB Biotherapeutics | $3.18 | +1.92% | −16.3% | — | — | — | $289.3M | Compare |
| FENCFennec Pharmaceuticals | $10.35 | −3.27% | +44.2% | +85.2% | 11.0% | — | $362.9M | Compare |
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
